A decade of liver organoids: Advances in disease modeling

키워드

참고문헌 (197)

1. Trefts E, "The liver", Curr Biol, 27, pp.R1147~R1151 (2017)
2. Schulze RJ, "The cell biology of the hepatocyte : A membrane trafficking machine", J Cell Biol, 218, pp.2096~2112 (2019)
3. Zhou Z, "Hepatocytes : a key cell type for innate immunity", Cell Mol Immunol, 13, pp.301~315 (2016)
4. Malik R, "The role of non-parenchymal cells in liver growth", Semin Cell Dev Biol, 13, pp.425~431 (2002)
5. Kumar S, "Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis", Adv Drug Deliv Rev, 176, pp.113869~ (2021)
6. Cheemerla S, "Global epidemiology of chronic liver disease", Clin Liver Dis(Hoboken), 17, pp.365~370 (2021)
7. Moon AM, "Contemporary epidemiology of chronic liver disease and cirrhosis", Clin Gastroenterol Hepatol, 18, pp.2650~2666 (2020)
8. Yu JH, "Organoids as research models for hepatocellular carcinoma", Exp Cell Res, 411, pp.112987~ (2022)
9. Liu Y, "Animal models of chronic liver diseases", Am J Physiol Gastrointest Liver Physiol, 304, pp.G449~G468 (2013)
10. Ortiz C, "Extracellular matrix remodeling in chronic liver disease", Curr Tissue Microenviron Rep, 2, pp.41~52 (2021)
11. Simian M, "Organoids : A historical perspective of thinking in three dimensions", J Cell Biol, 216, pp.31~40 (2017)
12. Corrò C, "A brief history of organoids", Am J Physiol Cell Physiol, 319, pp.C151~C165 (2020)
13. Evans MJ, "Establishment in culture of pluripotential cells from mouse embryos", Nature, 292, pp.154~156 (1981)
14. Thomson JA, "Embryonic stem cell lines derived from human blastocysts", Science, 282, pp.1145~1147 (1998)
15. Kim J, "Human organoids : model systems for human biology and medicine", Nat Rev Mol Cell Biol, 21, pp.571~584 (2020)
16. Lancaster MA, "Cerebral organoids model human brain development and microcephaly", Nature, 501, pp.373~379 (2013)
17. Dye BR, "In vitro generation of human pluripotent stem cell derived lung organoids", Elife, 4, pp.e05098~ (2015)
18. Takasato M, "Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis", Nature, 526, pp.564~568 (2015)
19. McCracken KW, "Modelling human development and disease in pluripotent stem-cell-derived gastric organoids", Nature, 516, pp.400~404 (2014)
20. Spence JR, "Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro", Nature, 470, pp.105~109 (2011)
21. Breunig M, "Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells", Cell Stem Cell, 28, pp.1105~1124 (2021)
22. Mun SJ, "Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids", J Hepatol, 71, pp.970~985 (2019)
23. Takebe T, "Vascularized and functional human liver from an iPSCderived organ bud transplant", Nature, 499, pp.481~484 (2013)
24. Rowe RG, "Induced pluripotent stem cells in disease modelling and drug discovery", Nat Rev Genet, 20, pp.377~388 (2019)
25. Li ML, "Influence of a reconstituted basement membrane and its components on casein gene expression and secretion in mouse mammary epithelial cells", Proc Natl Acad Sci U S A, 84, pp.136~140 (1987)
26. Shannon JM, "Functional differentiation of alveolar type II epithelial cells in vitro : effects of cell shape, cell-matrix interactions and cell-cell interactions", Biochim Biophys Acta, 931, pp.143~156 (1987)
27. Sato T, "Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche", Nature, 459, pp.262~265 (2009)
28. Hu H, "Long-term expansion of functional mouse and human hepatocytes as 3D organoids", Cell, 175, pp.1591~1606 (2018)
29. Sato T, "Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium", Gastroenterology, 141, pp.1762~1772 (2011)
30. Bartfeld S, "In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection", Gastroenterology, 148, pp.126~136 (2015)
31. Yee C, "Threedimensional modelling of ovarian cancer : From cell lines to organoids for discovery and personalized medicine", Front Bioeng Biotechnol, 10, pp.836984~ (2022)
32. van de Wetering M, "Prospective derivation of a living organoid biobank of colorectal cancer patients", Cell, 161, pp.933~945 (2015)
33. Boj SF, "Organoid models of human and mouse ductal pancreatic cancer", Cell, 160, pp.324~338 (2015)
34. Li X, "Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics", Nat Commun, 9, pp.2983~ (2018)
35. Broutier L, "Human primary liver cancerderived organoid cultures for disease modeling and drug screening", Nat Med, 23, pp.1424~1435 (2017)
36. Martínez AK, "Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies", Curr Pathobiol Rep, 2, pp.143~153 (2014)
37. Fiorotto R, "Liver diseases in the dish : iPSC and organoids as a new approach to modeling liver diseases", Biochim Biophys Acta Mol Basis Dis, 1865, pp.920~928 (2019)
38. Vinken M, "Primary hepatocyte cultures for liver disease modeling", Curr Opin Toxicol, 25, pp.1~5 (2021)
39. Arzumanian VA, "The curious case of the HepG2 cell line : 40 years of expertise", Int J Mol Sci, 22, pp.13135~ (2021)
40. Nuciforo S, "Organoids to model liver disease", JHEP Rep, 3, pp.100198~ (2020)
41. Lam DTUH, "Emerging liver organoid platforms and technologies", Cell Regen, 10, pp.27~ (2021)
42. Marsee A, "Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids", Cell Stem Cell, 28, pp.816~832 (2021)
43. Fagiuoli S, "Monogenic diseases that can be cured by liver transplantation", J Hepatol, 59, pp.595~612 (2013)
44. Lachmann RH, "Enzyme replacement therapy for lysosomal storage diseases", Curr Opin Pediatr, 23, pp.588~593 (2011)
45. Walshe JM, "Chelation treatment of neurological Wilson’s disease", Q J Med, 86, pp.197~204 (1993)
46. Boudes PF, "Gene therapy as a new treatment option for inherited monogenic diseases", Eur J Intern Med, 25, pp.31~36 (2014)
47. Huch M, "Long-term culture of genome-stable bipotent stem cells from adult human liver", Cell, 160, pp.299~312 (2015)
48. Caiazza C, "Liver organoids: Updates on disease modeling and biomedical applications", Biology(Basel), 10, pp.835~ (2021)
49. Gómez-Mariano G, "Liver organoids reproduce alpha-1antitrypsin deficiency-related liver disease", Hepatol Int, 14, pp.127~137 (2020)
50. Fromme M, "Alpha-1 antitrypsin deficiency : A re-surfacing adult liver disorder", J Hepatol, 76, pp.946~958 (2022)
51. Andersson ER, "Mouse model of alagille syndrome and mechanisms of Jagged1 missense mutations", Gastroenterology, 154, pp.1080~1095 (2018)
52. Kruitwagen HS, "Long-term survival of transplanted autologous canine liver organoids in a COMMD1-deficient dog model of metabolic liver disease", Cells, 9, pp.410~ (2020)
53. Nantasanti S, "Disease modeling and gene therapy of copper storage disease in canine hepatic organoids", Stem Cell Reports, 5, pp.895~907 (2015)
54. Shi Y, "Induced pluripotent stem cell technology : a decade of progress", Nat Rev Drug Discov, 16, pp.115~130 (2017)
55. Ogawa M, "Directed differentiation of cholangiocytes from human pluripotent stem cells", Nat Biotechnol, 33, pp.853~861 (2015)
56. Sampaziotis F, "Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation", Nat Biotechnol, 33, pp.845~852 (2015)
57. Shinozawa T, "High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids", Gastroenterology, 160, pp.831~846 (2021)
58. Ouchi R, "Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids", Cell Metab, 30, pp.374~384 (2019)
59. Ramli MNB, "Human pluripotent stem cell-derived organoids as models of liver disease", Gastroenterology, 159, pp.1471~1486 (2020)
60. Shteinberg M, "Cystic fibrosis", Lancet, 397, pp.2195~2211 (2021)
61. Guan Y, "Human hepatic organoids for the analysis of human genetic diseases", JCI Insight, 2, pp.e94954~ (2017)
62. Akbari S, "Robust, long-term culture of endoderm-derived hepatic organoids for disease modeling", Stem Cell Reports, 13, pp.627~641 (2019)
63. Graffmann N, "In vitro differentiation of pluripotent stem cells into hepatocyte like cells-Basic principles and current progress", Stem Cell Res, 61, pp.102763~ (2022)
64. Kvist AJ, "Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines", Biochem Pharmacol, 155, pp.124~140 (2018)
65. Ma H, "The nuclear receptor THRB facilitates differentiation of human PSCs into more mature hepatocytes", Cell Stem Cell, 29, pp.795~809 (2022)
66. Yang J, "The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels", Cancer Med, 11, pp.1357~1370 (2022)
67. Saltsman JA, "A human organoid model of aggressive hepatoblastoma for disease modeling and drug testing", Cancers(Basel), 12, pp.2668~ (2020)
68. Lin J, "Epidemiological characteristics of primary liver cancer in mainland China from 2003 to 2020 : A representative multicenter study", Front Oncol, 12, pp.906778~ (2022)
69. Piñero F, "Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina", World J Hepatol, 10, pp.41~50 (2018)
70. Teschke R, "Hepatocellular carcinoma in alcoholic liver disease : mechanistic considerations and clinical facts", Hepatoma Res, 5, pp.40~ (2019)
71. Al-Salama ZT, "Lenvatinib : A review in hepatocellular carcinoma", Drugs, 79, pp.665~674 (2019)
72. Personeni N, "Lenvatinib for the treatment of unresectable hepatocellular carcinoma : evidence to date", J Hepatocell Carcinoma, 6, pp.31~39 (2019)
73. Madden K, "Immune checkpoint inhibitors in lung cancer and melanoma", Semin Oncol Nurs, 35, pp.150932~ (2019)
74. Feng GS, "Improving the efficacy of liver cancer immunotherapy : The power of combined preclinical and clinical studies", Hepatology, 73(Suppl 1), pp.104~114 (2021)
75. Marquardt JU, "Functional and genetic deconstruction of the cellular origin in liver cancer", Nat Rev Cancer, 15, pp.653~667 (2015)
76. Ding X, "Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas", Gastroenterology, 157, pp.1630~1645 (2019)
77. Harding JJ, "Prospective genotyping of hepatocellular carcinoma : Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies", Clin Cancer Res, 25, pp.2116~2126 (2019)
78. Lin DC, "Genomic and epigenomic heterogeneity of hepatocellular carcinoma", Cancer Res, 77, pp.2255~2265 (2017)
79. Okrah K, "Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology", NPJ Precis Oncol, 2, pp.25~ (2018)
80. Rebouissou S, "Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression", Hepatology, 64, pp.2047~2061 (2016)
81. Ishii T, "Analysis of HBV genomes integrated into the genomes of human hepatoma PLC", PRF, Genes(Basel), pp.2020, 11[DOI]
82. Kamatani Y, "A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians", Nat Genet, 41, pp.591~595 (2009)
83. Sze KM, "Hepatitis B Virus-telomerase reverse transcriptase promoter integration harnesses host ELF4, resulting in telomerase reverse transcriptase gene transcription in hepatocellular carcinoma", Hepatology, 73, pp.23~40 (2021)
84. Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
85. Curtius K, "An evolutionary perspective on field cancerization", Nat Rev Cancer, 18, pp.19~32 (2018)
86. Greten FR, "Inflammation and cancer : Triggers, mechanisms, and consequences", Immunity, 51, pp.27~41 (2019)
87. Takai A, "Threedimensional organotypic culture models of human hepatocellular carcinoma", Sci Rep, 6, pp.21174~ (2016)
88. He X, "EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells", Sci Rep, 12, pp.8007~ (2022)
89. Nuciforo S, "Organoid models of human liver cancers derived from tumor needle biopsies", Cell Rep, 24, pp.1363~1376 (2018)
90. Xu H, "Organoid technology and applications in cancer research", J Hematol Oncol, 11, pp.116~ (2018)
91. Wu LJ, "Organoids of liver diseases : From bench to bedside", World J Gastroenterol, 25, pp.1913~1927 (2019)
92. El-Serag HB, "Hepatocellular carcinoma : epidemiology and molecular carcinogenesis", Gastroenterology, 132, pp.2557~2576 (2007)
93. Zhou C, "Integrated analysis of copy number variations and gene expression profiling in hepatocellular carcinoma", Sci Rep, 7, pp.10570~ (2017)
94. Li L, "Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity", JCI Insight, 4, pp.e121490~ (2019)
95. Cao W, "LGR5 marks targetable tumor-initiating cells in mouse liver cancer", Nat Commun, 11, pp.1961~ (2020)
96. Artegiani B, "Probing the tumor suppressor function of BAP1 in CRISPR-engineered human liver organoids", Cell Stem Cell, 24, pp.927~943 (2019)
97. Chan-On W, "Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers", Nat Genet, 45, pp.1474~1478 (2013)
98. Yang L, "Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis", Protein Cell, 13, pp.683~688 (2022)
99. Huch M, "In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration", Nature, 494, pp.247~250 (2013)
100. Sun L, "Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes", Nat Cell Biol, 21, pp.1015~1026 (2019)
101. Huang P, "Direct reprogramming of human fibroblasts to functional and expandable hepatocytes", Cell Stem Cell, 14, pp.370~384 (2014)
102. Zheng K, "c-MYC-making liver sick:Role of c-MYC in hepatic cell function, homeostasis and disease", Genes(Basel), 8, pp.123~ (2017)
103. Sun L, "Progress in human liver organoids", J Mol Cell Biol, 12, pp.607~617 (2020)
104. Dijkstra KK, "Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine", Cell Rep, 31, pp.107588~ (2020)
105. Gao D, "Organoid cultures derived from patients with advanced prostate cancer", Cell, 159, pp.176~187 (2014)
106. Fujii M, "A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis", Cell Stem Cell, 18, pp.827~838 (2016)
107. Cao W, "Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors", Carcinogenesis, 40, pp.145~154 (2019)
108. Protzer U, "Living in the liver : hepatic infections", Nat Rev Immunol, 12, pp.201~213 (2012)
109. Global hepatitis report 2017, "World Health Organization", World Health Organization, ~ (2017)
110. Fanning GC, "Therapeutic strategies for hepatitis B virus infection : towards a cure", Nat Rev Drug Discov, 18, pp.827~844 (2019)
111. Roca Suarez AA, "HBV 2021 : New therapeutic strategies against an old foe", Liver Int, 41(Suppl 1), pp.15~23 (2021)
112. Degasperi E, "Bulevirtide for patients with compensated chronic hepatitis delta : A review", Liver Int (2022)[DOI]
113. Nassal M, "HBV cccDNA : viral persistence reservoir and key obstacle for a cure of chronic hepatitis B", Gut, 64, pp.1972~1984 (2015)
114. Manns MP, "Breakthroughs in hepatitis C research : from discovery to cure", Nat Rev Gastroenterol Hepatol, 19, pp.533~550 (2022)
115. Kolykhalov AA, "Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA", Science, 277, pp.570~574 (1997)
116. Yanagi M, "Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee", Proc Natl Acad Sci U S A, 94, pp.8738~8743 (1997)
117. Baktash Y, "Single particle imaging of polarized hepatoma organoids upon hepatitis C virus infection reveals an ordered and sequential entry process", Cell Host Microbe, 23, pp.382~394 (2018)
118. Ko C, "DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level", J Virol, 88, pp.13689~13698 (2014)
119. Nishitsuji H, "Investigating the hepatitis B virus life cycle using engineered reporter hepatitis B viruses", Cancer Sci, 109, pp.241~249 (2018)
120. Verrier ER, "A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses", Hepatology, 63, pp.35~48 (2016)
121. Lucifora J, "Control of hepatitis B virus replication by innate response of HepaRG cells", Hepatology, 51, pp.63~72 (2010)
122. Macovei A, "Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells", J Virol, 84, pp.243~253 (2010)
123. Ni Y, "Hepatitis B and D viruses exploit sodium taurocholate cotransporting polypeptide for species-specific entry into hepatocytes", Gastroenterology, 146, pp.1070~1083 (2014)
124. Schulze A, "Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans", Hepatology, 46, pp.1759~1768 (2007)
125. Sureau C, "A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant", Hepatology, 57, pp.985~994 (2013)
126. Hantz O, "Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells", J Gen Virol, 90, pp.127~135 (2009)
127. Sakurai F, "Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection", Sci Rep, 7, pp.45698~ (2017)
128. Shlomai A, "Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems", Proc Natl Acad Sci U S A, 111, pp.12193~12198 (2014)
129. Xia Y, "Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions", J Hepatol, 66, pp.494~503 (2017)
130. Nie YZ, "Recapitulation of hepatitis B virus-host interactions in liver organoids from human induced pluripotent stem cells", EBioMedicine, 35, pp.114~123 (2018)
131. De Crignis E, "Application of human liver organoids as a patientderived primary model for HBV infection and related hepatocellular carcinoma", Elife, 10, pp.e60747~ (2021)
132. Medhat A, "Hepatitis B x antigen(HBx)is an important therapeutic target in the pathogenesis of hepatocellular carcinoma", Oncotarget, 12, pp.2421~2433 (2021)
133. Ma XX, "Prevalence and clinical features of hepatitis E virus infection in pregnant women : A large cohort study in Inner Mongolia, China", Clin Res Hepatol Gastroenterol, 45, pp.101536~ (2021)
134. Kinast V, "Hepatitis E virus drug development", Viruses, 11, pp.485~ (2019)
135. Li P, "Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids", Sci Adv, 8, pp.eabj5908~ (2022)
136. Yang L, "A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids", Cell Stem Cell, 27, pp.125~136 (2020)
137. Richards A, "SARS-CoV-2 infection of human pluripotent stem cell-derived liver organoids reveals potential mechanisms of liver pathology", iScience, 25, pp.105146~ (2022)
138. Zhao B, "Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids", Protein Cell, 11, pp.771~775 (2020)
139. Zhao Y, "Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids", Gut, 72, pp.216~218 (2023)
140. McCarron S, "Functional characterization of organoids derived from irreversibly damaged liver of patients with NASH", Hepatology, 74, pp.1825~1844 (2021)
141. Lagana SM, "Hepatic pathology in patients dying of COVID-19 : a series of 40 cases including clinical, histologic, and virologic data", Mod Pathol, 33, pp.2147~2155 (2020)
142. Wang Y, "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19", J Hepatol, 73, pp.807~816 (2020)
143. Weber S, "Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection : a prospective cohort study", Gut, 70, pp.1925~1932 (2021)
144. Muus C, "Single-cell meta-analysis of SARSCoV-2 entry genes across tissues and demographics", Nat Med, 27, pp.546~559 (2021)
145. Ji D, "Non-alcoholic fatty liver diseases in patients with COVID-19 : A retrospective study", J Hepatol, 73, pp.451~453 (2020)
146. Loomba R, "The global NAFLD epidemic", Nat Rev Gastroenterol Hepatol, 10, pp.686~690 (2013)
147. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver diseaseMeta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
148. Boeckmans J, "Human-based systems : Mechanistic NASH modelling just around the corner?", Pharmacol Res, 134, pp.257~267 (2018)
149. Li Z, "Prevalence of nonalcoholic fatty liver disease in mainland of China : a meta-analysis of published studies", J Gastroenterol Hepatol, 29, pp.42~51 (2014)
150. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
151. Wong RJ, "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States", Gastroenterology, 148, pp.547~555 (2015)
152. Berná G, "The role of nutrition in non-alcoholic fatty liver disease : Pathophysiology and management", Liver Int, 40(Suppl 1), pp.102~108 (2020)
153. Bazick J, "Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD : Guidelines for referral in NAFLD", Diabetes Care, 38, pp.1347~1355 (2015)
154. Huang PL, "A comprehensive definition for metabolic syndrome", Dis Model Mech, 2, pp.231~237 (2009)
155. Portillo-Sanchez P, "High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels", J Clin Endocrinol Metab, 100, pp.2231~2238 (2015)
156. Schwimmer JB, "Heritability of nonalcoholic fatty liver disease", Gastroenterology, 136, pp.1585~1592 (2009)
157. Anstee QM, "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort", J Hepatol, 73, pp.505~515 (2020)
158. Abul-Husn NS, "A protein-truncating HSD17B13 variant and protection from chronic liver disease", N Engl J Med, 378, pp.1096~1106 (2018)
159. Gerges SH, "Non-alcoholic fatty liver disease : An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions", Life Sci, 271, pp.119220~ (2021)
160. Satapathy SK, "Epidemiology and natural history of nonalcoholic fatty liver disease", Semin Liver Dis, 35, pp.221~235 (2015)
161. Wang XJ, "Nonalcoholic fatty liver disease", Ann Intern Med, 169, pp.ITC65~ITC80 (2018)
162. Day CP, "Steatohepatitis : a tale of two"hits"?", Gastroenterology, 114, pp.842~845 (1998)
163. Buzzetti E, "The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)", Metabolism, 65, pp.1038~1048 (2016)
164. Fukuda N, "Interactions between fatty acid synthesis, oxidation, and esterification in the production of triglyceriderich lipoproteins by the liver", J Lipid Res, 25, pp.831~842 (1984)
165. Caligiuri A, "Molecular pathogenesis of NASH", Int J Mol Sci, 17, pp.1575~ (2016)
166. Takaki A, "Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis(NASH)", Int J Mol Sci, 15, pp.7352~7379 (2014)
167. Alisi A, "The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications", Mediators Inflamm, 2017, pp.8162421~ (2017)
168. Deng CJ, "Role of B lymphocytes in the pathogenesis of NAFLD : A 2022 update", Int J Mol Sci, 23, pp.12376~ (2022)
169. Gehrke N, "Metabolic inflammation-A role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?", Gastroenterology, 158, pp.1929~1947 (2020)
170. Hassan K, "Nonalcoholic fatty liver disease : a comprehensive review of a growing epidemic", World J Gastroenterol, 20, pp.12082~12101 (2014)
171. Loomba R, "Mechanisms and disease consequences of nonalcoholic fatty liver disease", Cell, 184, pp.2537~2564 (2021)
172. Peverill W, "Evolving concepts in the pathogenesis of NASH : beyond steatosis and inflammation", Int J Mol Sci, 15, pp.8591~8638 (2014)
173. Hansen HH, "Mouse models of nonalcoholic steatohepatitis in preclinical drug development", Drug Discov Today, 22, pp.1707~1718 (2017)
174. Lau JK, "Animal models of non-alcoholic fatty liver disease : current perspectives and recent advances", J Pathol, 241, pp.36~44 (2017)
175. Chen W, "Patatin-like phospholipase domain-containing 3", adiponutrin deficiency in mice is not associated with fatty liver disease, 2010, pp.52, 1134~1142
176. Tilson SG, "Modeling PNPLA3-associated NAFLD using human-induced pluripotent stem cells", Hepatology, 74, pp.2998~3017 (2021)
177. Kershaw EE, "Adipose triglyceride lipase : function, regulation by insulin, and comparison with adiponutrin", Diabetes, 55, pp.148~157 (2006)
178. Lake AC, "Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members", J Lipid Res, 46, pp.2477~2487 (2005)
179. Wang SX, "Advancements in MAFLD modeling with human cell and organoid models", Int J Mol Sci, 23, pp.11850~ (2022)
180. Collin de l’Hortet A, "Generation of human fatty livers using custom-engineered induced pluripotent stem cells with modifiable SIRT1 metabolism", Cell Metab, 30, pp.385~401 (2019)
181. Kimura M, "En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH", Cell, 185, pp.4216~4232 (2022)
182. Wang S, "Human ESCderived expandable hepatic organoids enable therapeutic liver repopulation and pathophysiological modeling of alcoholic liver injury", Cell Res, 29, pp.1009~1026 (2019)
183. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
184. Segovia-Miranda F, "Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression", Nat Med, 25, pp.1885~1893 (2019)
185. Chen Y, "Mechanisms of ductular reaction in non-alcoholic steatohepatitis", World J Gastroenterol, 28, pp.2088~2099 (2022)
186. Ben-Moshe S, "Spatial heterogeneity in the mammalian liver", Nat Rev Gastroenterol Hepatol, 16, pp.395~410 (2019)
187. Purushotham A, "Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation", Cell Metab, 9, pp.327~338 (2009)
188. Bhatia SN, "Microfluidic organs-on-chips", Nat Biotechnol, 32, pp.760~772 (2014)
189. Wang Y, "Modeling human nonalcoholic fatty liver disease(NAFLD)with an organoids-on-a-chip system", ACS Biomater Sci Eng, 6, pp.5734~5743 (2020)
190. Ratziu V, "Why do so many NASH trials fail?", Gastroenterology (2020)[DOI]
191. Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT):a multicentre, randomised, placebo-controlled trial", Lancet, 385, pp.956~965 (2015)
192. Pharm I, "INT 747 (obeticholic acid) fails to achieve goals in Japanese study for non-alcoholic steatohepatitis (NASH)", The Netherlands: European Association for the Study of the Liver, ~ (2015)
193. Takebe T, "Human iPSC-derived miniature organs : a tool for drug studies", Clin Pharmacol Ther, 96, pp.310~313 (2014)
194. Yang K, "Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity", Clin Pharmacol Ther, 96, pp.589~598 (2014)
195. Au SH, "Hepatic organoids for microfluidic drug screening", Lab Chip, 14, pp.3290~3299 (2014)
196. Russmann S, "Current concepts of mechanisms in drug-induced hepatotoxicity", Curr Med Chem, 16, pp.3041~3053 (2009)
197. Seitz HK, "Alcoholic liver disease", Nat Rev Dis Primers, 4, pp.16~ (2018)

관련 논문AI추천